464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts)

Subjects

Subjects :

Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Details

Language :

English

ISSN :

20511426

Volume :

9

Issue :

Suppl 2

Database :

Directory of Open Access Journals

Journal :

Journal for ImmunoTherapy of Cancer

Publication Type :

Academic Journal

Accession number :

edsdoj.b9bdce9175d74090a82d14e103d95ea2

Document Type :

article

Full Text :

https://doi.org/10.1136/jitc-2021-SITC2021.464